ICON Public Limited (ICLR) 6-K 25 Jul 24 2024 Q2 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2024
Cover [Abstract]
Document Type	6-K
Document Fiscal Year Focus	2024
Entity Registrant Name	ICON plc
Amendment Flag	false
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001060955
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2024

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 506,553	$ 378,102
Available for sale investments	0	1,954
Accounts receivable, net of allowance for credit losses	1,569,642	1,790,322
Unbilled revenue	1,230,948	951,936
Other receivables	78,113	65,797
Prepayments and other current assets	139,244	132,105
Income taxes receivable	79,216	91,254
Total current assets	3,603,716	3,411,470
Non-current assets:
Property, plant and equipment	353,844	361,184
Goodwill	9,016,549	9,022,075
Intangible assets	3,632,354	3,855,865
Operating right-of-use assets	149,782	140,333
Other receivables	87,609	78,470
Deferred tax asset	74,787	73,662
Investments in equity - long term	50,220	46,804
Total Assets	16,968,861	16,989,863
Current liabilities:
Accounts payable	83,037	131,584
Unearned revenue	1,602,526	1,654,507
Other liabilities	999,071	915,399
Income taxes payable	27,935	13,968
Current bank credit lines, loan facilities and notes	29,762	110,150
Total current liabilities	2,742,331	2,825,608
Non-current liabilities:
Non-current bank credit lines, loan facilities and notes	3,408,157	3,665,439
Lease liabilities	145,464	126,321
Non-current other liabilities	48,372	45,998
Non-current income taxes payable	195,778	186,654
Deferred tax liability	843,633	899,100
Commitments and contingencies	0	0
Total Liabilities	7,383,735	7,749,120
Shareholders' Equity:
Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized, 82,683,805 shares issued and outstanding at March 31, 2024 and 82,495,086 shares issued and outstanding at December 31, 2023	6,720	6,699
Additional paid-in capital	6,988,736	6,942,669
Other undenominated capital	1,162	1,162
Accumulated other comprehensive loss	(179,559)	(143,506)
Retained earnings	2,768,067	2,433,719
Total Shareholders' Equity	9,585,126	9,240,743
Total Liabilities and Shareholders' Equity	$ 16,968,861	$ 16,989,863

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - € / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value (in EUR cents per share)	€ 0.06	€ 0.06
Ordinary shares, shares authorized (in shares)	100,000,000	100,000,000
Ordinary shares, shares issued (in shares)	82,816,600	82,495,086
Ordinary shares, shares outstanding (in shares)	82,816,600	82,495,086

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 2,120,159	$ 2,020,251	$ 4,210,545	$ 3,998,829
Costs and expenses:
Direct costs (excluding depreciation and amortization)	1,493,600	1,429,540	2,964,967	2,825,086
Selling, general and administrative	194,458	187,806	371,808	387,812
Depreciation and amortization	149,635	145,059	298,816	290,185
Transaction and integration related	6,820	12,701	13,811	24,083
Restructuring	45,789	35,661	45,789	45,390
Total costs and expenses	1,890,302	1,810,767	3,695,191	3,572,556
Income from operations	229,857	209,484	515,354	426,273
Interest income	1,237	949	3,167	2,021
Interest expense	(60,840)	(85,206)	(132,505)	(171,757)
Income before income tax expense	170,254	125,227	386,016	256,537
Income tax expense	(23,344)	(9,629)	(51,668)	(23,902)
Income before share of losses from equity method investments	146,910	115,598	334,348	232,635
Share of losses from equity method investments	0	0	0	(383)
Net income	$ 146,910	$ 115,598	$ 334,348	$ 232,252
Net income per Ordinary Share (note 13):
Basic (in USD per share)	$ 1.78	$ 1.41	$ 4.04	$ 2.84
Diluted (in USD per share)	$ 1.76	$ 1.40	$ 4.02	$ 2.81
Weighted average number of Ordinary Shares outstanding (note 13):
Basic (in shares)	82,738,765	81,999,746	82,658,984	81,892,662
Diluted (in shares)	83,360,841	82,627,933	83,260,144	82,617,391

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Net Income (Loss) Attributable to Parent [Abstract]
Net income	$ 146,910		$ 115,598		$ 334,348	$ 232,252
Other comprehensive income, net of tax:
Currency translation adjustment	(8,985)	$ (32,040)	(10,638)	$ 15,500	(41,025)	4,862
(Loss) / gain on cash flow hedge	(4,112)	9,084	14,006	(3,858)	4,972	10,148
Total comprehensive income	$ 133,813	$ 164,482	$ 118,966	$ 128,296	$ 298,295	$ 247,262

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Ordinary shares	Additional Paid-in Capital	Other Undenominated Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Beginning balance (in shares) at Dec. 31, 2022		81,723,555
Beginning balance at Dec. 31, 2022	$ 8,497,963	$ 6,649	$ 6,840,306	$ 1,162	$ (171,538)	$ 1,821,384
Comprehensive income, net of tax:
Net income	116,654					116,654
Currency translation adjustment	15,500				15,500
(Loss) / gain on cash flow hedge	(3,858)				(3,858)
Total comprehensive income	128,296
Exercise of share options (in shares)		136,649
Exercise of share options	12,936	$ 9	12,927
Issue of restricted share units / performance share units (in shares)		68,218
Issue of restricted share units / performance share units	4	$ 4
Shared based compensation expense	14,658		14,658
Share issuance costs	(4)		(4)
Ending balance (in shares) at Mar. 31, 2023		81,928,422
Ending balance at Mar. 31, 2023	8,653,853	$ 6,662	6,867,887	1,162	(159,896)	1,938,038
Beginning balance (in shares) at Dec. 31, 2022		81,723,555
Beginning balance at Dec. 31, 2022	8,497,963	$ 6,649	6,840,306	1,162	(171,538)	1,821,384
Comprehensive income, net of tax:
Currency translation adjustment	4,862
(Loss) / gain on cash flow hedge	10,148
Total comprehensive income	247,262
Ending balance (in shares) at Jun. 30, 2023		82,151,049
Ending balance at Jun. 30, 2023	8,796,440	$ 6,676	6,891,494	1,162	(156,528)	2,053,636
Beginning balance (in shares) at Mar. 31, 2023		81,928,422
Beginning balance at Mar. 31, 2023	8,653,853	$ 6,662	6,867,887	1,162	(159,896)	1,938,038
Comprehensive income, net of tax:
Net income	115,598					115,598
Currency translation adjustment	(10,638)				(10,638)
(Loss) / gain on cash flow hedge	14,006				14,006
Total comprehensive income	118,966
Exercise of share options (in shares)		93,304
Exercise of share options	7,229	$ 6	7,223
Issue of restricted share units / performance share units (in shares)		129,323
Issue of restricted share units / performance share units	8	$ 8
Shared based compensation expense	16,389		16,389
Share issuance costs	(5)		(5)
Ending balance (in shares) at Jun. 30, 2023		82,151,049
Ending balance at Jun. 30, 2023	$ 8,796,440	$ 6,676	6,891,494	1,162	(156,528)	2,053,636
Beginning balance (in shares) at Dec. 31, 2023	82,495,086	82,495,086
Beginning balance at Dec. 31, 2023	$ 9,240,743	$ 6,699	6,942,669	1,162	(143,506)	2,433,719
Comprehensive income, net of tax:
Net income	187,438					187,438
Currency translation adjustment	(32,040)				(32,040)
(Loss) / gain on cash flow hedge	9,084				9,084
Total comprehensive income	164,482
Exercise of share options (in shares)		156,527
Exercise of share options	16,303	$ 10	16,293
Issue of restricted share units / performance share units (in shares)		32,192
Issue of restricted share units / performance share units	2	$ 2
Shared based compensation expense	11,121		11,121
Share issuance costs	(4)		(4)
Ending balance (in shares) at Mar. 31, 2024		82,683,805
Ending balance at Mar. 31, 2024	$ 9,432,647	$ 6,711	6,970,079	1,162	(166,462)	2,621,157
Beginning balance (in shares) at Dec. 31, 2023	82,495,086	82,495,086
Beginning balance at Dec. 31, 2023	$ 9,240,743	$ 6,699	6,942,669	1,162	(143,506)	2,433,719
Comprehensive income, net of tax:
Currency translation adjustment	(41,025)
(Loss) / gain on cash flow hedge	4,972
Total comprehensive income	$ 298,295
Ending balance (in shares) at Jun. 30, 2024	82,816,600	82,816,600
Ending balance at Jun. 30, 2024	$ 9,585,126	$ 6,720	6,988,736	1,162	(179,559)	2,768,067
Beginning balance (in shares) at Mar. 31, 2024		82,683,805
Beginning balance at Mar. 31, 2024	9,432,647	$ 6,711	6,970,079	1,162	(166,462)	2,621,157
Comprehensive income, net of tax:
Net income	146,910					146,910
Currency translation adjustment	(8,985)				(8,985)
(Loss) / gain on cash flow hedge	(4,112)				(4,112)
Total comprehensive income	133,813
Exercise of share options (in shares)		45,127
Exercise of share options	5,334	$ 3	5,331
Issue of restricted share units / performance share units (in shares)		87,668
Issue of restricted share units / performance share units	6	$ 6
Shared based compensation expense	13,336		13,336
Share issuance costs	$ (10)		(10)
Ending balance (in shares) at Jun. 30, 2024	82,816,600	82,816,600
Ending balance at Jun. 30, 2024	$ 9,585,126	$ 6,720	$ 6,988,736	$ 1,162	$ (179,559)	$ 2,768,067

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash flows from operating activities:
Net income	$ 146,910	$ 115,598	$ 334,348	$ 232,252
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense			298,816	290,185
Impairment of operating right-of-use assets and related property, plant and equipment			12,559	8,613
Reduction in carrying value of operating right-of-use assets			19,367	23,607
Loss on equity method investments	0	0	0	383
Acquisition-related gain			0	(6,160)
Amortization of financing costs and debt discount			20,604	7,899
Stock compensation expense			28,145	31,357
Deferred tax benefit			(61,239)	(59,177)
Unrealized foreign exchange movements			13,761	(3,345)
Other non-cash items			12,463	18,202
Changes in operating assets and liabilities:
Accounts receivable			198,749	(40,675)
Unbilled revenue			(287,183)	(27,210)
Unearned revenue			(52,081)	65,266
Other net assets			7,356	(161,816)
Net cash provided by operating activities			545,665	379,381
Cash flows from investing activities:
Purchase of property, plant and equipment			(63,440)	(58,880)
Purchase of subsidiary undertakings (net of cash acquired)			(7,831)	(5,100)
Movement of available for sale investments			1,954	60
Proceeds from investments in equity - long term			1,373	0
Purchase of investments in equity - long term			(5,621)	(4,733)
Net cash used in investing activities			(73,565)	(68,653)
Cash flows from financing activities:
New Notes issue costs			(11,679)	0
Drawdown of credit lines and loan facilities			2,192,480	230,000
Repayment of credit lines and loan facilities			(2,537,882)	(580,000)
Proceeds from exercise of equity compensation			21,645	20,177
Share issue costs			(14)	(9)
Net cash used in financing activities			(335,450)	(329,832)
Effect of exchange rate movements on cash			(8,199)	512
Net increase / (decrease) in cash and cash equivalents			128,451	(18,592)
Cash and cash equivalents at beginning of period			378,102	288,768	$ 288,768
Cash and cash equivalents at end of period	$ 506,553	$ 270,176	$ 506,553	$ 270,176	$ 378,102

Basis of presentation

Basis of presentation	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation These condensed consolidated financial statements which have been prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) have not been audited. The condensed consolidated financial statements reflect all adjustments, which are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the condensed consolidated financial statements. Actual results could differ from those estimates. The condensed consolidated financial statements should be read in conjunction with the accounting policies and notes to the consolidated financial statements included in ICON’s Form 20-F for the year ended December 31, 2023 (see note 2 - Summary of significant accounting policies ). Operating results for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal period ending December 31, 2024.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Revenue recognition The Company earns revenues by providing a number of different services to its customers. These services, which are integral elements of the clinical development process, include clinical trials management, consulting, contract staffing, data services and laboratory services. These services, which are described below, can be purchased collectively or individually as part of a clinical trial contract. There is not significant variability in how economic factors affect these services. Contracts range in duration from a number of months to several years. ASC 606 requires application of five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies the performance obligation(s), which have been applied to revenue recognized from each service described below. Clinical trial service revenue A clinical trial service is a single performance obligation satisfied over time, i.e. the full-service obligation in respect of a clinical trial (including those services performed by investigators and other parties) is considered a single performance obligation. Promises offered to the customer are not distinct within the context of the contract. ICON is the contract principal in respect of both direct services and in the use of third parties (principally investigator services) that support the clinical research projects. The transaction price is determined by reference to the contract or change order value (total service revenue and pass-through/ reimbursable expenses) adjusted to reflect a realizable contract value. Revenue is recognized over time as the single performance obligation is satisfied. The progress towards completion for clinical service contracts is measured based on an input measure being total project costs incurred (inclusive of pass-through/ reimbursable expenses) at each reporting period as a percentage of forecasted total project costs. Laboratory services revenue Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the products or services are transferred to the customer. Revenue for laboratory services is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Where contracts with customers contain multiple performance obligations, the transaction price is allocated to each performance obligation based on the estimated relative selling price of the promised good or service. Service revenue is recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The determination of the methodology to measure progress requires judgment and is based on the nature of services provided. This requires an assessment of the transfer of value to the customer. The right to invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds to the value of the Company's performance and the transfer of value to the customer. Contracting services revenue The Company has availed of the practical expedient which results in recognition of revenue on a right to invoice basis. Application of the practical expedient reflects the right to consideration from the customer in an amount that corresponds directly with the value to the customer of the performance completion to date. This reflects hours performed by contract staff. Consulting services revenue Our consulting services contracts represent a single performance obligation satisfied over time. The transaction price is determined by reference to contract or change order value. Revenue is recognized over time as the performance obligation is satisfied. The progress towards completion for consulting contracts is measured based on total project inputs (time) at each reporting period as a percentage of forecasted total project inputs. Data services revenue The Company provides data reports and analytics to customers based on agreed-upon specifications, including the timing of delivery, which is typically either weekly, monthly, or quarterly. If a customer requests more than one type of data report or series of data reports within a contract, each distinct type of data report is a separate performance obligation. The contracts provide for the Company to be compensated for the value of each deliverable. The transaction price is determined using list prices, discount agreements, if any, and negotiations with the customers, and generally includes any out-of-pocket expenses. Typically, the Company bills in advance of services being provided with the amount being recorded as unearned revenue. When multiple performance obligations exist, the transaction price is allocated to performance obligations on a relative standalone selling price basis. In cases where the Company contracts to provide a series of data reports, or in some cases data, the Company recognizes revenue over time using the “units delivered” output method as the data or reports are delivered. Expense reimbursements are recorded to revenue as the expenses are incurred as they relate directly to the services performed. Certain arrangements include upfront customization or consultative services for customers. These arrangements often include payments based on the achievement of certain contractual milestones. Under these arrangements, the Company contracts with a customer to carry out a specific study, ultimately resulting in delivery of a custom report or data product. These arrangements are a single performance obligation given the integrated nature of the service being provided. The Company typically recognizes revenue under these contracts over time, using an output-based measure, generally time elapsed, to measure progress and transfer of control of the performance obligation to the customer. Expense reimbursements are recorded to revenue as the expenses are incurred as they relate directly to the service performed. The Company enters into contracts with some of its larger data suppliers that involve non-monetary terms. The Company issues purchase credits to be used toward the data supplier's purchase of the Company's services based on the fair value of the data obtained. In exchange, the Company receives monetary discounts on the data received from the data suppliers. The fair value of the revenue earned from the customer purchases is recognized as services are delivered as described above. At the end of the contract year, any unused customer purchase credits may be forfeited or carried over to the next contract year based on the terms of the data supplier contract. Commissions Incremental costs of obtaining a contract are recognized as an asset on the Consolidated Balance Sheet in respect of those contracts that exceed one year. Where commission costs relate to contracts that are less than one year, the practical expedient is applied as the amortization period of the asset which would arise on deferral would be one year or less. Intangible Assets Intangible assets are measured at fair value at the date of acquisition and amortized on a straight-line basis over their respective estimated useful lives. The Company has no indefinite-lived intangible assets. The Company evaluates its intangible assets for impairment when indicators of impairment exist. Intangible assets are amortized on a straight-line basis over their estimated useful lives, as set forth in the table below: Estimated Useful Life Customer relationships 16 - 23 years Order backlog 3 years Trade names 3 years Patient database 7 years Technology assets 5 years The Company periodically assesses the estimated useful lives of intangible assets to evaluate whether what was established at acquisition continues to be appropriate. Income taxes The Company applies the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision of income taxes in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the amount that is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions will more likely than not be sustained. Recognized income tax positions are measured at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. Interest and penalties related to income taxes are included in income tax expense and classified with the related liability on the Consolidated Balance Sheet. The Company accounts for the impact of Global Intangible Low-Taxed Income ("GILTI") in the period it arises and has therefore not provided for deferred taxes in respect of this item. Recently Issued Accounting Standards Accounting pronouncements issued but not adopted as of June 30, 2024 In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting – Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which amends the guidance in ASC Topic 280, Segment Reporting. The amended guidance requires disclosure of significant segment expenses and other segment items on an annual and interim basis. Furthermore, all disclosures about a reportable segment’s profit or loss, which are currently required annually, will be mandated for interim periods. The additional disclosures required by ASU 2023-07 apply to entities with a single reportable segment. The amended guidance is effective for fiscal periods beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with retrospective application required. The Company is currently evaluating the impact of this ASU on disclosures within its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about an entity’s effective tax rate reconciliation and additional discloses on income taxes paid. The new requirements are effective for annual periods beginning after December 15, 2024. The guidance is to be applied prospectively, with an option for retrospective application. The Company is currently evaluating the impact of this new guidance on disclosures within its consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Revenue disaggregated by customer concentration is as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Clients 1-5 $ 523,535 $ 529,792 $ 1,067,495 $ 1,092,220 Clients 6-10 308,689 284,382 628,424 563,908 Clients 11-25 458,119 420,880 886,149 829,047 Other 829,816 785,197 1,628,477 1,513,654 Total $ 2,120,159 $ 2,020,251 $ 4,210,545 $ 3,998,829 There was no revenue from individual customers greater than 10% of consolidated revenue in the respective periods. Accounts receivables and unbilled revenue are as follows: June 30, December 31, (in thousands) Billed services (accounts receivable) $ 1,604,945 $ 1,821,855 Allowance for credit losses (35,303) (31,533) Accounts receivable (net) 1,569,642 1,790,322 Unbilled services (unbilled revenue) 1,230,948 951,936 Accounts receivable and unbilled revenue, net $ 2,800,590 $ 2,742,258 Unbilled services and unearned revenue or payments on account (contract assets and liabilities) were as follows: (in thousands, except percentages) June 30, December 31, $ Change % Change Unbilled services (unbilled revenue) $ 1,230,948 $ 951,936 $ 279,012 29.3 % Unearned revenue (payments on account) (1,602,526) (1,654,507) 51,981 (3.1) % Net balance $ (371,578) $ (702,571) $ 330,993 (47.1) % Timing may differ between the satisfaction of performance obligations and the invoicing and collection of amounts related to our contracts with customers. We record assets for amounts related to performance obligations that are satisfied but not yet billed and/or collected. These assets are recorded as unbilled services and therefore contract assets rather than accounts receivables when receipt of the consideration is conditional on something other than the passage of time. Liabilities are recorded for amounts that are collected in advance of the satisfaction of performance obligations or billed in advance of the revenue being earned. Unbilled services/revenue balances arise where invoicing or billing is based on the timing of agreed milestones related to service contracts for clinical research. Contractual billing arrangements in respect of certain reimbursable expenses (principally investigators) require billing by the investigator to the Company prior to billing by the Company to the customer. As there is no contractual right to set-off between unbilled services (contract assets) and unearned revenue (contract liabilities), each are separately presented gross on the Condensed Consolidated Balance Sheet. Unbilled services as at June 30, 2024 increased by $279.0 million compared to December 31, 2023. Unearned revenue decreased by $52.0 million over the same period resulting in a decrease of $331.0 million in the net balance of unbilled services and unearned revenue or payments on account between December 31, 2023 and June 30, 2024. These fluctuations are primarily due to timing of payments and invoicing related to the Group's clinical trial management contracts. Billings and payments are established by contractual provisions including predetermined payment schedules which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. Unbilled services arise from long-term contracts when a cost-based input method of revenue recognition is applied and revenue recognized exceeds the amount billed to the customer.

Accounts receivable, unbilled r

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities)	Revenue Revenue disaggregated by customer concentration is as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Clients 1-5 $ 523,535 $ 529,792 $ 1,067,495 $ 1,092,220 Clients 6-10 308,689 284,382 628,424 563,908 Clients 11-25 458,119 420,880 886,149 829,047 Other 829,816 785,197 1,628,477 1,513,654 Total $ 2,120,159 $ 2,020,251 $ 4,210,545 $ 3,998,829 There was no revenue from individual customers greater than 10% of consolidated revenue in the respective periods. Accounts receivables and unbilled revenue are as follows: June 30, December 31, (in thousands) Billed services (accounts receivable) $ 1,604,945 $ 1,821,855 Allowance for credit losses (35,303) (31,533) Accounts receivable (net) 1,569,642 1,790,322 Unbilled services (unbilled revenue) 1,230,948 951,936 Accounts receivable and unbilled revenue, net $ 2,800,590 $ 2,742,258 Unbilled services and unearned revenue or payments on account (contract assets and liabilities) were as follows: (in thousands, except percentages) June 30, December 31, $ Change % Change Unbilled services (unbilled revenue) $ 1,230,948 $ 951,936 $ 279,012 29.3 % Unearned revenue (payments on account) (1,602,526) (1,654,507) 51,981 (3.1) % Net balance $ (371,578) $ (702,571) $ 330,993 (47.1) % Timing may differ between the satisfaction of performance obligations and the invoicing and collection of amounts related to our contracts with customers. We record assets for amounts related to performance obligations that are satisfied but not yet billed and/or collected. These assets are recorded as unbilled services and therefore contract assets rather than accounts receivables when receipt of the consideration is conditional on something other than the passage of time. Liabilities are recorded for amounts that are collected in advance of the satisfaction of performance obligations or billed in advance of the revenue being earned. Unbilled services/revenue balances arise where invoicing or billing is based on the timing of agreed milestones related to service contracts for clinical research. Contractual billing arrangements in respect of certain reimbursable expenses (principally investigators) require billing by the investigator to the Company prior to billing by the Company to the customer. As there is no contractual right to set-off between unbilled services (contract assets) and unearned revenue (contract liabilities), each are separately presented gross on the Condensed Consolidated Balance Sheet. Unbilled services as at June 30, 2024 increased by $279.0 million compared to December 31, 2023. Unearned revenue decreased by $52.0 million over the same period resulting in a decrease of $331.0 million in the net balance of unbilled services and unearned revenue or payments on account between December 31, 2023 and June 30, 2024. These fluctuations are primarily due to timing of payments and invoicing related to the Group's clinical trial management contracts. Billings and payments are established by contractual provisions including predetermined payment schedules which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. Unbilled services arise from long-term contracts when a cost-based input method of revenue recognition is applied and revenue recognized exceeds the amount billed to the customer.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Six Months Year June 30, December 31, (in thousands) Opening balance $ 9,022,075 $ 8,971,670 Current period acquisition 2,732 36,750 Foreign exchange movement (8,258) 13,655 Closing balance $ 9,016,549 $ 9,022,075 On January 9, 2024, the Company acquired HumanFirst Inc. ("HumanFirst"), a life sciences technology company in exchange for consideration of $13.3 million. The net cash outflow was $7.8 million comprising initial cash payments of $11.8 million net of cash acquired of $4.0 million. $1.5 million of deferred consideration remains unpaid as of June 30, 2024. The purchase price allocation, as of the date of acquisition, was based on a preliminary valuation and may be subject to revision. Preliminarily, the HumanFirst acquisition resulted in the initial recognition of goodwill of $2.7 million and a developed technology intangible asset of $9.9 million . Preliminary goodwill arising in connection with the acquisition is primarily attributable to the assembled workforce of HumanFirst. The intangible asset will be amortized over its useful life of 5 years and in total, $1.0 million has been amortized in the period since the date of acquisition. There were no additional acquisitions during the second quarter of 2024 nor any impairment charges for the six months ended June 30, 2024 or the year ended December 31, 2023.

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets	Intangible assets The carrying amount of Intangible Assets for the periods ended June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, (in thousands) Cost Customer relationships $ 4,089,261 $ 4,090,393 Order backlog 540,795 541,302 Trade names & brands 204,621 204,653 Patient database 170,348 170,366 Technology assets 150,933 141,257 Total cost 5,155,958 5,147,971 Accumulated amortization (1,523,604) (1,292,106) Net book value $ 3,632,354 $ 3,855,865 In the six months ended June 30, 2024, the amortization expense recognized by the Company w as $233.0 million (ye ar ended December 31, 2023: $459.9 million). On January 9, 2024, the Company acquired HumanFirst. The acquisition resulted in the recognition of a developed technology intangible asset of $9.9 million. Refer to note 5. Goodwill for further details. The identifiable intangible assets are amortized over their estimated useful lives

Fair value measurements

Fair value measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs. The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short maturities of these instruments. As of June 30, 2024, the fair value of the major classes of the Company's assets and liabilities measured at fair value on a recurring basis were as follows: Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total (in thousands) Assets: Investments in equity- long term (b) $ — $ — $ — $ 50,220 $ 50,220 Total assets $ — $ — $ — $ 50,220 $ 50,220 As of December 31, 2023, the fair value of the major classes of the Company's assets and liabilities measured at fair value on a recurring basis were as follows: Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total (in thousands) Assets: Available for sale securities (short-term) (a) $ 1,954 $ — $ — $ — $ 1,954 Investments in equity- long term (b) — — — 46,804 46,804 Total assets $ 1,954 $ — $ — $ 46,804 $ 48,758 Liabilities: Derivative instruments (c) — 2,411 — — 2,411 Total liabilities $ — $ 2,411 $ — $ — $ 2,411 (a) Represents the fair value of highly liquid investments with maturities greater than three months, a minimum "A-" rated fixed term deposit and are based on quoted market prices. (b) To determine the classification of its interests in long-term investments, the Company considered the nature of its investment, the extent of influence over operating and financial decisions and the availability of readily determinable fair values. The Company determined that the interests in funds meet the definition of equity securities without readily determinable fair values, which qualify for the Net Asset Value (NAV) practical expedient in ASC 820 'Fair value measurement'. Any increases or decreases in fair value are recognized in net income in the period. (c) Represents the fair value of the interest rate caps and the interest rate swap. Non-recurring Fair Value Measurements Certain assets and liabilities are carried on the accompanying Condensed Consolidated Balance Sheet at cost and are not re-measured to fair value on a recurring basis. These assets include finite-lived intangible assets that are tested for impairment when a triggering event occurs and goodwill that is tested for impairment annually or when a triggering event occurs. As of June 30, 2024, assets carried on the balance sheet which are not re-measured to fair value on a recurring basis totaled $12,648.9 million (December 31, 2023: $12,878.0 million) and are identified as Level 3 assets. These assets are comprised of goodwill of $9,016.5 million (December 31, 2023: $9,022.1 million) and net identifiable intangible assets of $3,632.4 million (December 31, 2023: $3,855.9 million). The estimated fair value of the Company’s debt wa s $3,469.3 million at June 30, 2024 (December 31, 2023: $3,793.5 million). The fair values of the Senior Secured Credit Facilities, the 2026 Notes and the New Notes were determined based on Level 2 inputs, which are based on rates at which the debt is traded among financial institutions. The fair value of the senior secured revolving loan facility is recorded as its carrying value, due to the short term duration. Refer to note 10. Bank credit lines, loan facilities and notes for further details on the Company's financing arrangements.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the six months ended June 30, 2024, a restructuring charge of $45.8 million ( June 30, 2023 : $45.4 million) was recorded in the Condensed Consolidated Statement of Operations under a restructuring plan adopted following a review of operations. The restructuring plan reflected a workforce reduction of $31.7 million ( June 30, 2023 : $34.1 million) and an office consolidation program to optimize the Company's office footprint of $14.1 million ( June 30, 2023 : $11.3 million), being the impairment of operating right-off-use assets and related property plant and equipment of $12.6 million ( June 30, 2023 : $8.6 million) and onerous contract costs of $1.5 million ( June 30, 2023 : $2.7 million) . Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Restructuring charges $ 45,789 $ 35,661 $ 45,789 $ 45,390 Total $ 45,789 $ 35,661 $ 45,789 $ 45,390 At June 30, 2024, a total liability of $26.3 million ( December 31, 2023: $7.0 million ) was recorded on the Consolidated Balance Sheet relating to restructuring activities. Six Months Ended Year June 30, December 31, 2023 (in thousands) Opening provision $ 6,999 $ 6,022 Charge during the period* 33,230 36,704 Utilization (13,883) (35,727) Closing provision $ 26,346 $ 6,999 *The charge for the period reflects the workforce reduction of $31.7 million and onerous contract costs of $1.5 million. The closing provision of $26.3 million reflects: (1) $21.6 million (December 31, 2023: $4.0 million) of personnel related liabilities as a result of the workforce reduction; all of which have been classified as short-term within Other Liabilities, and (2) $4.7 million (December 31, 2023: $3.0 million) of facilities related liabilities of which $1.2 million (December 31, 2023: $1.0 million) is included within Other liabilities and $3.5 million (December 31, 2023: $2.0 million)

Operating leases

Operating leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Operating leases	Operating leases Lease costs recorded under operating leases for three and six months ended June 30, 2024 and June 30, 2023 were as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Operating lease costs $ 9,287 $ 12,818 $ 22,450 $ 25,689 Income from sub-leases (301) (283) (637) (561) Net operating lease costs $ 8,986 $ 12,535 $ 21,813 $ 25,128 Of the total cost of $9.0 million incurred in the three months ended June 30, 2024 ( June 30, 2023 : $12.5 million ), $8.0 million ( June 30, 2023 : $9.3 million ) is recorded within selling, general and administration costs and $1.0 million ( June 30, 2023 : $3.2 million ) is recorded within direct costs. Of the total cost of $21.8 million incurred in the six months ended June 30, 2024 (June 30, 2023: $25.1 million), $18.0 million (June 30, 2023: $19.3 million) is recorded within selling, general and administration costs and $3.8 million (June 30, 2023: $5.8 million) is recorded within direct costs. During the six months ended June 30, 2024 and June 30, 2023, costs incurred by the Group related to variable lease payments were de minimis. Right-of-use assets obtained, in exchange for lease obligations during the three months ended June 30, 2024, totaled $11.0 million (June 30, 2023: $10.2 million). Right-of-use assets obtained, in exchange for lease obligations during the six months ended June 30, 2024, totaled $46.6 million (June 30, 2023: $22.5 million). The weighted average remaining lease term and weighted-average discount rate at June 30, 2024 were 6.85 years and 3.71%, respec tively. The weighted average remaining lease term and weighted-average discount rate at December 31, 2023 were 6.72 years and 3.29%, respectively. Future minimum lease payments under non-cancelable leases as of June 30, 2024 were as follows: (in thousands) Year 1 $ 42,160 Year 2 38,053 Year 3 32,707 Year 4 25,968 Year 5 18,176 Thereafter 46,671 Total future minimum lease payments 203,735 Lease imputed interest (21,976) Total $ 181,759 ther liabilities

Bank credit lines, loan facilit

Bank credit lines, loan facilities and notes	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Bank credit lines, loan facilities and notes	Bank credit lines, loan facilities and notes The Company had the following debt outstanding as of June 30, 2024 and December 31, 2023: Interest rate as of Principal amount Maturity Date June 30, December 31, June 30, December 31, (in thousands) Senior Secured Term Loan July 2028 7.335 % 7.860 % $ 961,331 $ 3,251,213 Senior Secured Notes (the "2026 Notes") July 2026 2.875 % 2.875 % 500,000 500,000 Senior Secured Revolving Loan July 2026 — % 6.720 % — 55,000 Senior Secured Notes (the "2027 Notes")* May 2027 5.809 % 750,000 — Senior Secured Notes (the "2029 Notes")* May 2029 5.849 % 750,000 — Senior Secured Notes (the "2034 Notes")* May 2034 6.000 % 500,000 — Total debt 3,461,331 3,806,213 Less current portion of debt (29,762) (110,150) Total long-term debt 3,431,569 3,696,063 Less debt issuance costs and debt discount (23,412) (30,624) Total long-term debt, net $ 3,408,157 $ 3,665,439 *Issued May 8, 2024 As of June 30, 2024, the contractual maturities of the Company's debt obligations were as follows: Contractual maturities of debt (in thousands) 2024 (remaining) $ 14,881 2025 29,762 2026 529,762 2027 779,762 2028 and thereafter 2,107,164 Total $ 3,461,331 The Company's primary financing arrangements are its senior secured credit facilities (the "Senior Secured Credit Facilities"), which consists of a senior secured term loan and a revolving credit facility, the 2026 Notes and the New Notes. The New Notes On May 8, 2024, ICON Investments Six Designated Activity Company (the "Issuer"), a wholly-owned subsidiary of ICON plc, issued $2 billion senior secured notes ("the New Notes"). The New Notes were issued in aggregate principal amounts of: $750 million 5.809% Senior Secured Notes due 2027 (the "2027 Notes"), $750 million 5.849% Senior Secured Notes due 2029 (the "2029 Notes") and $500 million 6.000% Senior Secured Notes due 2034 (the "2034 Notes"). The Company paid an underwriting discount of $6.8 million on the New Notes being: 0.250% of the principal amount of the 2027 Notes, 0.350% of the principal amount of the 2029 Notes and 0.450% of the 2034 Notes. Further, the 2034 Notes were issued at a discount of $0.5 million (issued at 99.896% of par). Interest on the New Notes is payable on May 8 and November 8 of each year, commencing on November 8, 2024. Unless previously redeemed, the 2027 Notes will mature on May 8, 2027, the 2029 Notes will mature on May 8, 2029 and the 2034 Notes will mature on May 8, 2034. The New Notes are guaranteed on a senior secured basis by ICON and its existing and future wholly owned subsidiaries, in each case that guarantee the obligations under our Senior Secured Credit Facilities and the 2026 Notes. The New Notes are the senior secured obligation of the Issuer and the Guarantors and rank equally in right of payment to all of the Issuer’s and Guarantors’ existing and future senior debt and senior in right of payment to all of the Issuer's and Guarantors' existing and future subordinated debt. The New Notes and the guarantees are secured on a first-lien basis by substantially all of the existing and future assets of the Issuer and the Guarantors that also secure the Issuer’s and the Guarantors’ obligations under the Senior Secured Credit Facilities and the 2026 Notes on a pari passu basis, subject to permitted liens, and the liens on the collateral securing the New Notes rank equally in priority with the liens on the collateral securing borrowings and guarantees under the Senior Secured Credit Facilities, the 2026 Notes and any other future pari passu first lien indebtedness. Senior Secured Credit Facilities On July 1, 2021, the Company completed the acquisition of PRA Health Sciences, Inc. ("PRA") by means of a merger whereby Indigo Merger Sub, Inc., a Delaware corporation and subsidiary of ICON, merged with and into PRA, the parent of the PRA Health Sciences ("the Merger"). In conjunction with the completion of the Merger, on July 1, 2021, ICON entered into a credit agreement providing for a senior secured term loan facility of $5,515 million and a senior secured revolving loan facility in an initial aggregate principal amount of $300 million (the "Senior Secured Credit Facilities"). On May 2, 2023, the Company agreed with its lenders to increase the aggregate principal amount of the senior secured revolving loan facility from $300 million to $500 million. Borrowings under the senior secured term loan facility amortize in equal quarterly installments in an amount equal to 1.00% per annum of the principal amount, with the remaining balance due at final maturity. The interest rate margin applicable to borrowings under the senior secured term loan facility is USD Term SOFR and a Term SOFR Adjustment depending on the interest period chosen plus an applicable margin which is dependent on the Company's net leverage ratio. At June 30, 2024, the applicable margin is 2.0% (which reflects the Third Amendment). The senior secured term loan facility is subject to a floor of 0.50%. Reflecting the Third Amendment, the interest rate margin applicable to borrowings under the revolving loan facility will be, at the option of the borrower, either (i) the applicable base rate plus an applicable margin of 0.45%, 0.10% or –% based on the Company’s current corporate family rating assigned by S&P of BB (or lower), BB+ or BBB- (or higher), respectively, or (ii) Term SOFR plus a Term SOFR Adjustment on the interest period chosen plus an applicable margin of 1.45%, 1.10%, 0.85%, 0.65%, or 0.50% based on the Company’s current corporate family rating assigned by S&P of BB (or lower), BB+, BBB-, BBB or BBB+ (or higher), respectively. In addition, lenders under the revolving loan facility are entitled to commitment fees as a percentage of the applicable margin at the time of drawing and utilization fees dependent on the proportion of the facility drawn. The Borrowers’ (as defined in the Senior Secured Credit Facility) obligations under the Senior Secured Credit Facilities are guaranteed by ICON and the subsidiary guarantors. The Senior Secured Credit Facilities are secured by a lien on substantially all of ICON’s, the Borrowers’ and each of the subsidiary guarantor’s assets (subject to certain exceptions), and the Senior Secured Credit Facilities will have a first-priority lien on such assets, which will rank pari passu with the lien securing the 2026 Notes and the New Notes subject to other permitted liens. The Company is permitted to make prepayments on the senior secured term loan without penalty. Principal repayments, comprising mandatory and voluntary repayments, during the six months ended June 30, 2024 and year ended December 31, 2023 were as follows: Principal repayments (in thousands) Quarter 1, 2023 $ 250,000 Quarter 2, 2023 150,000 Quarter 3, 2023 300,000 Quarter 4, 2023 250,000 Total repayments in 2023 950,000 Quarter 1, 2024 275,000 Quarter 2, 2024 2,014,882 Total repayments in 2024 $ 2,289,882 The voluntary repayment made during the quarter resulted in an accelerated charge associated with previously capitalized fees of $14.9 million (June 30, 2023: $1.2 million ). During t he six months ended June 30, 2024, the Company drew down $193.0 million of the senior secured revolving loan facility and repaid $248.0 million as shown below. As at June 30, 2024 , $nil (December 31, 2023: $55.0 million) was drawn under the senior secured revolving loan facility. Drawdown Repayment Closing Balance (in thousands) Quarter 1, 2023 $ 180,000 $ 100,000 $ 80,000 Quarter 2, 2023 50,000 80,000 50,000 Quarter 3, 2023 75,000 50,000 75,000 Quarter 4, 2023 65,000 85,000 55,000 Total drawdown/repayments in 2023 370,000 315,000 Quarter 1, 2024 50,000 55,000 50,000 Quarter 2, 2024 $ 143,000 $ 193,000 — Total drawdown/repayments in 2024 $ 193,000 $ 248,000 — 2026 Notes In addition to the Senior Secured Credit Facilities, on July 1, 2021, a subsidiary of the Company issued $500 million in aggregate principal amount of 2.875% senior secured notes (the "2026 Notes") in a private offering (the “Offering”). The 2026 Notes will mature on July 15, 2026. Fair Value of Debt The estimated fair value of the Company’s debt wa s $3,469.3 million a

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The Company previously entered into interest rate cap and swap agreements for purposes of managing its exposure to interest rate fluctuations. On November 29, 2022, the Company entered into two interest rate cap agreements ("2022 Caps") with an initial total notional value of $2,101 million to limit its exposure to changes in the variable interest rate on its Senior Secured Credit Facilities. Interest on the 2022 Caps began accruing on December 30, 2022 and the interest rate caps were due to expire on December 31, 2024. Under the terms of the interest rate caps, the Company had paid a fixed rate of 0.42% and received a variable rate equal to the amount that the three-month SOFR exceeds 4.75%. On November 29, 2022, the Company entered into an interest rate swap agreement ("2022 Swap") with an initial notional value of $1,101 million to limit its exposure to changes in the variable interest rate on its Senior Secured Credit Facilities. Interest on the 2022 Swap was due to begin accruing on December 31, 2024 and the interest rate swap was due to expire on September 30, 2026. Under the terms of the interest rate swap, the Company would have paid a fixed rate of 3.4% and would have received a variable rate of interest equal to the three-month SOFR on the 2022 Swap. The 2022 Caps and the 2022 Swap were designated as cash flow hedges. Gains and losses were initially reported as a component of other comprehensive income/loss and subsequently recognized in net income. During the quarter ended June 30, 2024, the Company’s exposure to interest rate fluctuations significantly reduced with the voluntary and mandatory repayments made of $2,014.9 million of the senior secured term loan facility. Given this reduction and the repricing of the Senior Secured Credit facilities (which occurred during the quarter ended March 31, 2024), the Company closed the 2022 Caps and 2022 Swap agreements. As at June 30, 2024, 72% of the Company’s outstanding debt is at a fixed interest rate (December 31, 2023: 13%). The fair value of the Company’s derivative financial instruments, on a gross basis, are summarized in the following table: June 30, 2024 December 31, 2023 Asset Liability Notional Asset Liability Notional (in thousands) Interest Rate Caps $ — $ — $ — $ — $ 1,871 $ 1,600,606 Interest Rate Swap — — — — 540 1,100,606 Total derivatives designated as hedging instruments $ — $ — $ — $ — $ 2,411 $ 2,701,212 As of June 30, 2024, following the closure of the interest rate caps and interest rate swap, the Company derecognized the derivative positions (December 31, 2023: current derivative liability of $1.9 million within O ther liabilities on-current other liabilities During the three months ended June 30, 2024, the Company recognized a loss of $4.1 million (June 30, 2023: $14.0 million gain) within other comprehensive income/loss after a reclassification of $12.8 million gain (June 30, 2023: $1.4 million expense) from other comprehensive income/loss to the income statement.

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income taxes recognized during the three and six months ended June 30, 2024 and June 30, 2023, comprise: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Income Tax expense $ 23,344 $ 9,629 $ 51,668 $ 23,902 As at June 30, 2024 the Company maintains a $196.1 million liability (December 31, 2023: $187.1 million) for unrecognized tax benefit, which is comprised of $162.4 million (December 31, 2023: $160.0 million) related to items generating unrecognized tax benefits and $33.7 million (December 31, 2023: $27.1 million) for interest and penalties related to such items. The Company recognizes interest accrued on unrecognized tax benefits as an additional income tax expense. The Company has analyzed the filing positions in all of the significant federal, state and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. The only periods subject to audit by the major tax jurisdictions where the Company does business are the 2015 through 2023 tax years. During such audits, local tax authorities may challenge the positions taken by us in our tax returns.

Net income per ordinary share

Net income per ordinary share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net income per ordinary share	Net income per ordinary share Basic net income per ordinary share attributable to the Group has been computed by dividing net income available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income per ordinary share is computed by adjusting the weighted average number of ordinary shares outstanding during the period for all potentially dilutive ordinary shares outstanding during the period and adjusting net income for any changes in income or loss that would result from the conversion of such potential ordinary shares. There is no difference in net income used for basic and diluted net income per ordinary share. The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, 2024 June 30, 2023 Weighted average number of ordinary shares outstanding for basic net income per ordinary share 82,738,765 81,999,746 82,658,984 81,892,662 Effect of dilutive share options and other awards outstanding under share based compensation programs 622,076 628,187 601,160 724,729 Weighted average number of ordinary shares outstanding for diluted net income per ordinary share 83,360,841 82,627,933 83,260,144 82,617,391 Three Months Ended Six Months Ended June 30, June 30, June 30, 2024 June 30, 2023 Net income per Ordinary Share: Basic $ 1.78 $ 1.41 4.04 2.84 Diluted $ 1.76 $ 1.40 4.02 2.81

Share-based awards

Share-based awards	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-based awards	Share-based awards Share Options The following table summarizes option activity for the six months ended June 30, 2024: Options Weighted Weighted Outstanding at December 31, 2023 902,806 $ 142.96 4.42 Granted 68,380 $ 325.51 Exercised (201,654) $ 107.30 Outstanding at June 30, 2024 769,532 $ 168.52 4.55 Exercisable at June 30, 2024 535,883 $ 134.89 3.81 The Company issues ordinary shares for all options exercised. The total amount of fully vested share options which remained outstanding at June 30, 2024 was 535,883. Fully vested share options at June 30, 2024 have an average remaining contractual term of 3.81 years and an average exercise price of $134.89. Fair value of Stock Options Assumptions The weighted average fair value of options granted during the six months ended June 30, 2024 and June 30, 2023 was calculated using the Black-Scholes option pricing model. The weighted average grant date fair values and assumptions used were as follows: Six Months Ended June 30, June 30, Weighted average grant date fair value $ 115.76 $ 85.12 Assumptions: Expected volatility 36 % 33 % Dividend yield — % — % Risk-free interest rate 4.20 % 4.18 % Expected life 4.3 years 5 years Expected volatility is based on the historical volatility of our common stock over a period equal to the expected term of the options; the expected life represents the weighted average period of time that options granted are expected to be outstanding given consideration to vesting schedules and our historical experience of past vesting and termination patterns. The risk-free rate is based on the U.S. government zero-coupon bonds yield curve in effect at time of the grant for periods corresponding with the expected life of the option. Restricted Share Units and Performance Share Units On April 23, 2013, the Company adopted the 2013 Employees Restricted Share Unit and Performance Share Unit Plan (the "2013 RSU Plan") pursuant to which the Compensation and Organization Committee of the Company's Board of Directors may select any employee, or any Director holding a salaried office or employment with the Company, or a subsidiary to receive an award under the plan. On May 11, 2015, the 2013 RSU Plan was amended and restated in order to increase the number of shares that can be issued under the 2013 RSU Plan by 2.5 million shares. Accordingly, an aggregate of 4.1 million ordinary shares have been reserved for issuance under the 2013 RSU Plan. The shares are awarded at par value and vest over a service period. Awards under the 2013 RSU Plan may be settled in cash or shares at the option of the Company. No awards may be granted under the 2013 RSU Plan after May 11, 2025. On April 30, 2019, the Company approved the 2019 Consultants and Directors Restricted Share Unit Plan (the “2019 Consultants RSU Plan”), which was effective as of May 16, 2019, pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any consultant, adviser or non-executive Director retained by the Company, or a subsidiary to receive an award under the plan. 250,000 ordinary shares have been reserved for issuance under the 2019 Consultants RSU Plan. The awards are at par value and vest over a service period. Awards granted to non-executive directors vest over twelve months. No awards may be granted under the 2019 Consultants RSU Plan after May 16, 2029. The Company has awarded RSUs and PSUs to certain key individuals of the Group. The following table summarizes RSU and PSU activity for the six months ended June 30, 2024: PSU PSU RSU RSU Outstanding at December 31, 2023 105,256 $ 226.29 621,011 $ 218.27 Granted 48,626 $ 325.51 237,539 $ 318.49 Shares vested (9,975) $ 177.38 (109,885) $ 220.87 Forfeited (72,764) $ 252.86 (39,114) $ 221.86 Outstanding at June 30, 2024 71,143 $ 273.79 709,551 $ 251.22 The fair value of PSUs vested for the six months ended June 30, 2024 totaled $1.8 million (2023: $7.5 million). The fair value of RSUs vested for the six months ended June 30, 2024 totaled $24.3 million (2023: $28.3 million). The PSUs vest based on service and specified EPS targets over the periods 2022 - 2024, 2023 - 2025 and 2024 - 2026. Depending on the amount of EPS from 2022 to 2026, up to an additional 85,659 PSUs may also be granted. Stock compensation expense Stock compensation expense for the three and six months ended June 30, 2024 and June 30, 2023 has been allocated as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Direct costs $ 7,299 $ 6,420 $ 14,020 $ 12,088 Selling, general and administrative 7,665 10,178 14,125 19,269 Total $ 14,964 $ 16,598 $ 28,145 $ 31,357

Share capital

Share capital	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Share capital	Share capital The Company can acquire up to 10% of its outstanding ordinary shares (by way of redemption), in accordance with Irish law and the Company’s constitutional documents through open market share acquisitions. On February 20, 2024, the Company's Board of Directors authorized a new buyback program of up to $500 million of the outstanding ordinary shares of the Company. All ordinary shares that are redeemed under the buyback program will be canceled in accordance with the constitutional documents of the Company and the nominal value of these shares transferred to an undenominated capital fund as required under Irish Company law. Repurchases under the share buyback program may be effected from time to time in open market or privately negotiated transactions in accordance with agreed terms and limitations. The timing and amount of the repurchase transactions under this program will depend on a variety of factors, including market conditions and corporate and regulatory considerations. Depending upon results of operations, market conditions and the development of the economy, as well as other factors, generally we will consider share repurchases on an opportunistic basis from time to time. During the six months ended June 30, 2024 no shares were redeemed by the Company under this buyback program.

Business Segment and Geographic

Business Segment and Geographical Information	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Business Segment and Geographical Information	Business Segment and Geographical Information The Company is a CRO providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. It specializes in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. The Company has the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and has the operational flexibility to provide development services on a stand-alone basis or as part of an integrated "full-service" solution. The Company has expanded through internal growth, together with a number of strategic acquisitions to enhance its expertise and capabilities in certain areas of the clinical development process. The Company determines and presents operating segments based on the information that is internally provided to the chief operating decision maker, the (‘CODM’) in accordance with ASC 280, Segment Reporting . The Company determined that the CODM was comprised of the Chief Executive Officer and the Chief Financial Officer. The Company operates as one reportable segment, which is the provision of outsourced development services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. Revenues are allocated to individual entities based on where the work is performed in accordance with the Company's global transfer pricing model. Revenues and income from operations in Ireland are a function of our global contracting model and the Group’s transfer pricing model. ICON Ireland acts as the Group entrepreneur under the Company’s global transfer pricing model given its role in the development and management of the Group, its ownership of key intellectual property and customer relationships, its key role in the mitigation of risks faced by the Group and its responsibility for maintaining the Company’s global network. ICON Ireland enters into the majority of the Company’s customer contracts. ICON Ireland remunerates other operating entities in the Group on the basis of an arm’s length return for the services they perform in each of their local territories. The arm’s length return for each ICON entity is established to ensure that each of ICON Ireland and the ICON entities that are involved in the conduct of services for customers, earn an appropriate return having regard to the assets owned, risks borne, and functions performed by each entity from these intercompany transactions. The arm’s length return is reviewed annually to ensure that it is market appropriate. The geographic split of revenue disclosed for each region outside Ireland is the arm’s length revenue attributable to these entities. The residual revenues of the Group, once each ICON entity has been paid its respective intercompany service fee, generally fall to be retained by ICON Ireland. As such, revenues and income from operations in Ireland are a function of this global transfer pricing model and comprise revenues of the Group after deducting the arm’s length revenues attributable to the activities performed outside Ireland. The geographical distribution of the Company’s segment measures for the three and six months ended June 30, 2024 and June 30, 2023 and as at June 30, 2024 and December 31, 2023 is as follows: a) The distribution of revenue by geographical area was as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Ireland $ 702,858 $ 593,407 $ 1,355,543 $ 1,105,241 Rest of Europe 384,214 373,810 774,429 788,033 U.S. 792,370 848,019 1,601,855 1,692,423 Rest of World 240,717 205,015 478,718 413,132 Total $ 2,120,159 $ 2,020,251 $ 4,210,545 $ 3,998,829 b) The distribution of income from operations by geographical area was as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Ireland * $ 108,381 $ 125,896 $ 245,111 $ 177,223 Rest of Europe 39,629 22,489 93,140 82,255 U.S. 62,656 55,744 139,555 143,833 Rest of World 19,191 5,355 37,548 22,962 Total $ 229,857 $ 209,484 $ 515,354 $ 426,273 * Includes the full amount of the amortization charge associated with the intangible asset acquired in the Merger. c) The distribution of long-lived assets (property, plant and equipment and operating right-of-use assets), net, by geographical area was as follows: June 30, December 31, 2023 (in thousands) Ireland $ 206,141 $ 199,051 Rest of Europe 90,097 94,046 U.S. 152,706 159,245 Rest of World 54,682 49,175 Total $ 503,626 $ 501,517

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent events	Subsequent events The Company has evaluated subsequent events from the balance sheet date through to the date at which the financial statements were available to be issued. The Company has determined that there are no items to disclose.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Revenue recognition	Revenue recognition The Company earns revenues by providing a number of different services to its customers. These services, which are integral elements of the clinical development process, include clinical trials management, consulting, contract staffing, data services and laboratory services. These services, which are described below, can be purchased collectively or individually as part of a clinical trial contract. There is not significant variability in how economic factors affect these services. Contracts range in duration from a number of months to several years. ASC 606 requires application of five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligation in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies the performance obligation(s), which have been applied to revenue recognized from each service described below. Clinical trial service revenue A clinical trial service is a single performance obligation satisfied over time, i.e. the full-service obligation in respect of a clinical trial (including those services performed by investigators and other parties) is considered a single performance obligation. Promises offered to the customer are not distinct within the context of the contract. ICON is the contract principal in respect of both direct services and in the use of third parties (principally investigator services) that support the clinical research projects. The transaction price is determined by reference to the contract or change order value (total service revenue and pass-through/ reimbursable expenses) adjusted to reflect a realizable contract value. Revenue is recognized over time as the single performance obligation is satisfied. The progress towards completion for clinical service contracts is measured based on an input measure being total project costs incurred (inclusive of pass-through/ reimbursable expenses) at each reporting period as a percentage of forecasted total project costs. Laboratory services revenue Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the products or services are transferred to the customer. Revenue for laboratory services is measured as the amount of consideration we expect to receive in exchange for transferring products or services. Where contracts with customers contain multiple performance obligations, the transaction price is allocated to each performance obligation based on the estimated relative selling price of the promised good or service. Service revenue is recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The determination of the methodology to measure progress requires judgment and is based on the nature of services provided. This requires an assessment of the transfer of value to the customer. The right to invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds to the value of the Company's performance and the transfer of value to the customer. Contracting services revenue The Company has availed of the practical expedient which results in recognition of revenue on a right to invoice basis. Application of the practical expedient reflects the right to consideration from the customer in an amount that corresponds directly with the value to the customer of the performance completion to date. This reflects hours performed by contract staff. Consulting services revenue Our consulting services contracts represent a single performance obligation satisfied over time. The transaction price is determined by reference to contract or change order value. Revenue is recognized over time as the performance obligation is satisfied. The progress towards completion for consulting contracts is measured based on total project inputs (time) at each reporting period as a percentage of forecasted total project inputs. Data services revenue The Company provides data reports and analytics to customers based on agreed-upon specifications, including the timing of delivery, which is typically either weekly, monthly, or quarterly. If a customer requests more than one type of data report or series of data reports within a contract, each distinct type of data report is a separate performance obligation. The contracts provide for the Company to be compensated for the value of each deliverable. The transaction price is determined using list prices, discount agreements, if any, and negotiations with the customers, and generally includes any out-of-pocket expenses. Typically, the Company bills in advance of services being provided with the amount being recorded as unearned revenue. When multiple performance obligations exist, the transaction price is allocated to performance obligations on a relative standalone selling price basis. In cases where the Company contracts to provide a series of data reports, or in some cases data, the Company recognizes revenue over time using the “units delivered” output method as the data or reports are delivered. Expense reimbursements are recorded to revenue as the expenses are incurred as they relate directly to the services performed. Certain arrangements include upfront customization or consultative services for customers. These arrangements often include payments based on the achievement of certain contractual milestones. Under these arrangements, the Company contracts with a customer to carry out a specific study, ultimately resulting in delivery of a custom report or data product. These arrangements are a single performance obligation given the integrated nature of the service being provided. The Company typically recognizes revenue under these contracts over time, using an output-based measure, generally time elapsed, to measure progress and transfer of control of the performance obligation to the customer. Expense reimbursements are recorded to revenue as the expenses are incurred as they relate directly to the service performed. The Company enters into contracts with some of its larger data suppliers that involve non-monetary terms. The Company issues purchase credits to be used toward the data supplier's purchase of the Company's services based on the fair value of the data obtained. In exchange, the Company receives monetary discounts on the data received from the data suppliers. The fair value of the revenue earned from the customer purchases is recognized as services are delivered as described above. At the end of the contract year, any unused customer purchase credits may be forfeited or carried over to the next contract year based on the terms of the data supplier contract. Commissions Incremental costs of obtaining a contract are recognized as an asset on the Consolidated Balance Sheet in respect of those contracts that exceed one year. Where commission costs relate to contracts that are less than one year, the practical expedient is applied as the amortization period of the asset which would arise on deferral would be one year or less.
Intangible assets	Intangible Assets Intangible assets are measured at fair value at the date of acquisition and amortized on a straight-line basis over their respective estimated useful lives. The Company has no indefinite-lived intangible assets. The Company evaluates its intangible assets for impairment when indicators of impairment exist. Intangible assets are amortized on a straight-line basis over their estimated useful lives, as set forth in the table below: Estimated Useful Life Customer relationships 16 - 23 years Order backlog 3 years Trade names 3 years Patient database 7 years Technology assets 5 years The Company periodically assesses the estimated useful lives of intangible assets to evaluate whether what was established at acquisition continues to be appropriate.
Income taxes	Income taxes The Company applies the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amount of existing assets and liabilities and their respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision of income taxes in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the amount that is more likely than not to be realized. The Company recognizes the effect of income tax positions only if those positions will more likely than not be sustained. Recognized income tax positions are measured at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. Interest and penalties related to income taxes are included in income tax expense and classified with the related liability on the Consolidated Balance Sheet. The Company accounts for the impact of Global Intangible Low-Taxed Income ("GILTI") in the period it arises and has therefore not provided for deferred taxes in respect of this item.
Recently issues accounting standards	Recently Issued Accounting Standards Accounting pronouncements issued but not adopted as of June 30, 2024 In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting – Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which amends the guidance in ASC Topic 280, Segment Reporting. The amended guidance requires disclosure of significant segment expenses and other segment items on an annual and interim basis. Furthermore, all disclosures about a reportable segment’s profit or loss, which are currently required annually, will be mandated for interim periods. The additional disclosures required by ASU 2023-07 apply to entities with a single reportable segment. The amended guidance is effective for fiscal periods beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with retrospective application required. The Company is currently evaluating the impact of this ASU on disclosures within its consolidated financial statements.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets are amortized on a straight-line basis over their estimated useful lives, as set forth in the table below: Estimated Useful Life Customer relationships 16 - 23 years Order backlog 3 years Trade names 3 years Patient database 7 years Technology assets 5 years The carrying amount of Intangible Assets for the periods ended June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, (in thousands) Cost Customer relationships $ 4,089,261 $ 4,090,393 Order backlog 540,795 541,302 Trade names & brands 204,621 204,653 Patient database 170,348 170,366 Technology assets 150,933 141,257 Total cost 5,155,958 5,147,971 Accumulated amortization (1,523,604) (1,292,106) Net book value $ 3,632,354 $ 3,855,865

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Revenue disaggregated by customer concentration is as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Clients 1-5 $ 523,535 $ 529,792 $ 1,067,495 $ 1,092,220 Clients 6-10 308,689 284,382 628,424 563,908 Clients 11-25 458,119 420,880 886,149 829,047 Other 829,816 785,197 1,628,477 1,513,654 Total $ 2,120,159 $ 2,020,251 $ 4,210,545 $ 3,998,829

Accounts receivable, unbilled_2

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Accounts Receivables and Unbilled Revenue, and Unbilled Services and Unearned Revenue	Accounts receivables and unbilled revenue are as follows: June 30, December 31, (in thousands) Billed services (accounts receivable) $ 1,604,945 $ 1,821,855 Allowance for credit losses (35,303) (31,533) Accounts receivable (net) 1,569,642 1,790,322 Unbilled services (unbilled revenue) 1,230,948 951,936 Accounts receivable and unbilled revenue, net $ 2,800,590 $ 2,742,258 Unbilled services and unearned revenue or payments on account (contract assets and liabilities) were as follows: (in thousands, except percentages) June 30, December 31, $ Change % Change Unbilled services (unbilled revenue) $ 1,230,948 $ 951,936 $ 279,012 29.3 % Unearned revenue (payments on account) (1,602,526) (1,654,507) 51,981 (3.1) % Net balance $ (371,578) $ (702,571) $ 330,993 (47.1) %

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Six Months Year June 30, December 31, (in thousands) Opening balance $ 9,022,075 $ 8,971,670 Current period acquisition 2,732 36,750 Foreign exchange movement (8,258) 13,655 Closing balance $ 9,016,549 $ 9,022,075

Intangible assets (Tables)

Intangible assets (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets are amortized on a straight-line basis over their estimated useful lives, as set forth in the table below: Estimated Useful Life Customer relationships 16 - 23 years Order backlog 3 years Trade names 3 years Patient database 7 years Technology assets 5 years The carrying amount of Intangible Assets for the periods ended June 30, 2024 and December 31, 2023 is as follows: June 30, December 31, (in thousands) Cost Customer relationships $ 4,089,261 $ 4,090,393 Order backlog 540,795 541,302 Trade names & brands 204,621 204,653 Patient database 170,348 170,366 Technology assets 150,933 141,257 Total cost 5,155,958 5,147,971 Accumulated amortization (1,523,604) (1,292,106) Net book value $ 3,632,354 $ 3,855,865

Fair value measurements (Tables

Fair value measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis	As of June 30, 2024, the fair value of the major classes of the Company's assets and liabilities measured at fair value on a recurring basis were as follows: Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total (in thousands) Assets: Investments in equity- long term (b) $ — $ — $ — $ 50,220 $ 50,220 Total assets $ — $ — $ — $ 50,220 $ 50,220 As of December 31, 2023, the fair value of the major classes of the Company's assets and liabilities measured at fair value on a recurring basis were as follows: Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total (in thousands) Assets: Available for sale securities (short-term) (a) $ 1,954 $ — $ — $ — $ 1,954 Investments in equity- long term (b) — — — 46,804 46,804 Total assets $ 1,954 $ — $ — $ 46,804 $ 48,758 Liabilities: Derivative instruments (c) — 2,411 — — 2,411 Total liabilities $ — $ 2,411 $ — $ — $ 2,411 (a) Represents the fair value of highly liquid investments with maturities greater than three months, a minimum "A-" rated fixed term deposit and are based on quoted market prices. (b) To determine the classification of its interests in long-term investments, the Company considered the nature of its investment, the extent of influence over operating and financial decisions and the availability of readily determinable fair values. The Company determined that the interests in funds meet the definition of equity securities without readily determinable fair values, which qualify for the Net Asset Value (NAV) practical expedient in ASC 820 'Fair value measurement'. Any increases or decreases in fair value are recognized in net income in the period.
Fair Value, Assets Measured on Recurring Basis	As of June 30, 2024, the fair value of the major classes of the Company's assets and liabilities measured at fair value on a recurring basis were as follows: Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total (in thousands) Assets: Investments in equity- long term (b) $ — $ — $ — $ 50,220 $ 50,220 Total assets $ — $ — $ — $ 50,220 $ 50,220 As of December 31, 2023, the fair value of the major classes of the Company's assets and liabilities measured at fair value on a recurring basis were as follows: Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total (in thousands) Assets: Available for sale securities (short-term) (a) $ 1,954 $ — $ — $ — $ 1,954 Investments in equity- long term (b) — — — 46,804 46,804 Total assets $ 1,954 $ — $ — $ 46,804 $ 48,758 Liabilities: Derivative instruments (c) — 2,411 — — 2,411 Total liabilities $ — $ 2,411 $ — $ — $ 2,411 (a) Represents the fair value of highly liquid investments with maturities greater than three months, a minimum "A-" rated fixed term deposit and are based on quoted market prices. (b) To determine the classification of its interests in long-term investments, the Company considered the nature of its investment, the extent of influence over operating and financial decisions and the availability of readily determinable fair values. The Company determined that the interests in funds meet the definition of equity securities without readily determinable fair values, which qualify for the Net Asset Value (NAV) practical expedient in ASC 820 'Fair value measurement'. Any increases or decreases in fair value are recognized in net income in the period.

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Summary of Restructuring Charges	Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Restructuring charges $ 45,789 $ 35,661 $ 45,789 $ 45,390 Total $ 45,789 $ 35,661 $ 45,789 $ 45,390
Summary of Details of Movement in Restructuring Charges	Six Months Ended Year June 30, December 31, 2023 (in thousands) Opening provision $ 6,999 $ 6,022 Charge during the period* 33,230 36,704 Utilization (13,883) (35,727) Closing provision $ 26,346 $ 6,999

Operating leases (Tables)

Operating leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of Lease Costs	Lease costs recorded under operating leases for three and six months ended June 30, 2024 and June 30, 2023 were as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Operating lease costs $ 9,287 $ 12,818 $ 22,450 $ 25,689 Income from sub-leases (301) (283) (637) (561) Net operating lease costs $ 8,986 $ 12,535 $ 21,813 $ 25,128
Schedule of Operating Lease Maturity	Future minimum lease payments under non-cancelable leases as of June 30, 2024 were as follows: (in thousands) Year 1 $ 42,160 Year 2 38,053 Year 3 32,707 Year 4 25,968 Year 5 18,176 Thereafter 46,671 Total future minimum lease payments 203,735 Lease imputed interest (21,976) Total $ 181,759

Bank credit lines, loan facil_2

Bank credit lines, loan facilities and notes (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The Company had the following debt outstanding as of June 30, 2024 and December 31, 2023: Interest rate as of Principal amount Maturity Date June 30, December 31, June 30, December 31, (in thousands) Senior Secured Term Loan July 2028 7.335 % 7.860 % $ 961,331 $ 3,251,213 Senior Secured Notes (the "2026 Notes") July 2026 2.875 % 2.875 % 500,000 500,000 Senior Secured Revolving Loan July 2026 — % 6.720 % — 55,000 Senior Secured Notes (the "2027 Notes")* May 2027 5.809 % 750,000 — Senior Secured Notes (the "2029 Notes")* May 2029 5.849 % 750,000 — Senior Secured Notes (the "2034 Notes")* May 2034 6.000 % 500,000 — Total debt 3,461,331 3,806,213 Less current portion of debt (29,762) (110,150) Total long-term debt 3,431,569 3,696,063 Less debt issuance costs and debt discount (23,412) (30,624) Total long-term debt, net $ 3,408,157 $ 3,665,439 *Issued May 8, 2024 Drawdown Repayment Closing Balance (in thousands) Quarter 1, 2023 $ 180,000 $ 100,000 $ 80,000 Quarter 2, 2023 50,000 80,000 50,000 Quarter 3, 2023 75,000 50,000 75,000 Quarter 4, 2023 65,000 85,000 55,000 Total drawdown/repayments in 2023 370,000 315,000 Quarter 1, 2024 50,000 55,000 50,000 Quarter 2, 2024 $ 143,000 $ 193,000 — Total drawdown/repayments in 2024 $ 193,000 $ 248,000 —
Schedule of Contractual Maturities of Debt	As of June 30, 2024, the contractual maturities of the Company's debt obligations were as follows: Contractual maturities of debt (in thousands) 2024 (remaining) $ 14,881 2025 29,762 2026 529,762 2027 779,762 2028 and thereafter 2,107,164 Total $ 3,461,331
Schedule of Principal Payments on Debt Instrument	Principal repayments, comprising mandatory and voluntary repayments, during the six months ended June 30, 2024 and year ended December 31, 2023 were as follows: Principal repayments (in thousands) Quarter 1, 2023 $ 250,000 Quarter 2, 2023 150,000 Quarter 3, 2023 300,000 Quarter 4, 2023 250,000 Total repayments in 2023 950,000 Quarter 1, 2024 275,000 Quarter 2, 2024 2,014,882 Total repayments in 2024 $ 2,289,882

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The fair value of the Company’s derivative financial instruments, on a gross basis, are summarized in the following table: June 30, 2024 December 31, 2023 Asset Liability Notional Asset Liability Notional (in thousands) Interest Rate Caps $ — $ — $ — $ — $ 1,871 $ 1,600,606 Interest Rate Swap — — — — 540 1,100,606 Total derivatives designated as hedging instruments $ — $ — $ — $ — $ 2,411 $ 2,701,212

Income taxes (Tables)

Income taxes (Tables)	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	Income taxes recognized during the three and six months ended June 30, 2024 and June 30, 2023, comprise: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Income Tax expense $ 23,344 $ 9,629 $ 51,668 $ 23,902

Net income per ordinary share (

Net income per ordinary share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income per Ordinary Share	The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, 2024 June 30, 2023 Weighted average number of ordinary shares outstanding for basic net income per ordinary share 82,738,765 81,999,746 82,658,984 81,892,662 Effect of dilutive share options and other awards outstanding under share based compensation programs 622,076 628,187 601,160 724,729 Weighted average number of ordinary shares outstanding for diluted net income per ordinary share 83,360,841 82,627,933 83,260,144 82,617,391 Three Months Ended Six Months Ended June 30, June 30, June 30, 2024 June 30, 2023 Net income per Ordinary Share: Basic $ 1.78 $ 1.41 4.04 2.84 Diluted $ 1.76 $ 1.40 4.02 2.81

Share-based awards (Tables)

Share-based awards (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes option activity for the six months ended June 30, 2024: Options Weighted Weighted Outstanding at December 31, 2023 902,806 $ 142.96 4.42 Granted 68,380 $ 325.51 Exercised (201,654) $ 107.30 Outstanding at June 30, 2024 769,532 $ 168.52 4.55 Exercisable at June 30, 2024 535,883 $ 134.89 3.81
Schedule of Weighted Average Fair Values and Assumptions Used	The weighted average grant date fair values and assumptions used were as follows: Six Months Ended June 30, June 30, Weighted average grant date fair value $ 115.76 $ 85.12 Assumptions: Expected volatility 36 % 33 % Dividend yield — % — % Risk-free interest rate 4.20 % 4.18 % Expected life 4.3 years 5 years
Summary of RSU and PSU Activity	The following table summarizes RSU and PSU activity for the six months ended June 30, 2024: PSU PSU RSU RSU Outstanding at December 31, 2023 105,256 $ 226.29 621,011 $ 218.27 Granted 48,626 $ 325.51 237,539 $ 318.49 Shares vested (9,975) $ 177.38 (109,885) $ 220.87 Forfeited (72,764) $ 252.86 (39,114) $ 221.86 Outstanding at June 30, 2024 71,143 $ 273.79 709,551 $ 251.22
Schedule of Non-Cash Stock Compensation Expense	Stock compensation expense for the three and six months ended June 30, 2024 and June 30, 2023 has been allocated as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Direct costs $ 7,299 $ 6,420 $ 14,020 $ 12,088 Selling, general and administrative 7,665 10,178 14,125 19,269 Total $ 14,964 $ 16,598 $ 28,145 $ 31,357

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Distribution of Revenue by Geographical Area	The distribution of revenue by geographical area was as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Ireland $ 702,858 $ 593,407 $ 1,355,543 $ 1,105,241 Rest of Europe 384,214 373,810 774,429 788,033 U.S. 792,370 848,019 1,601,855 1,692,423 Rest of World 240,717 205,015 478,718 413,132 Total $ 2,120,159 $ 2,020,251 $ 4,210,545 $ 3,998,829
Schedule of Distribution of Income from Operations by Geographical Area	The distribution of income from operations by geographical area was as follows: Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, (in thousands) Ireland * $ 108,381 $ 125,896 $ 245,111 $ 177,223 Rest of Europe 39,629 22,489 93,140 82,255 U.S. 62,656 55,744 139,555 143,833 Rest of World 19,191 5,355 37,548 22,962 Total $ 229,857 $ 209,484 $ 515,354 $ 426,273
Schedule of Distribution of Depreciation and Amortization by Geographical Area	The distribution of long-lived assets (property, plant and equipment and operating right-of-use assets), net, by geographical area was as follows: June 30, December 31, 2023 (in thousands) Ireland $ 206,141 $ 199,051 Rest of Europe 90,097 94,046 U.S. 152,706 159,245 Rest of World 54,682 49,175 Total $ 503,626 $ 501,517

Summary of significant accoun_4

Summary of significant accounting policies - Schedule of Finite-Lived Intangible Assets (Details)	Jun. 30, 2024
Customer relationships | Minimum
Indefinite-Lived Intangible Assets [Line Items]
Estimated Useful Life	16 years
Customer relationships | Maximum
Indefinite-Lived Intangible Assets [Line Items]
Estimated Useful Life	23 years
Order backlog
Indefinite-Lived Intangible Assets [Line Items]
Estimated Useful Life	3 years
Trade names
Indefinite-Lived Intangible Assets [Line Items]
Estimated Useful Life	3 years
Patient database
Indefinite-Lived Intangible Assets [Line Items]
Estimated Useful Life	7 years
Technology assets
Indefinite-Lived Intangible Assets [Line Items]
Estimated Useful Life	5 years

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 2,120,159	$ 2,020,251	$ 4,210,545	$ 3,998,829
Clients 1-5
Disaggregation of Revenue [Line Items]
Revenue	523,535	529,792	1,067,495	1,092,220
Clients 6-10
Disaggregation of Revenue [Line Items]
Revenue	308,689	284,382	628,424	563,908
Clients 11-25
Disaggregation of Revenue [Line Items]
Revenue	458,119	420,880	886,149	829,047
Other
Disaggregation of Revenue [Line Items]
Revenue	$ 829,816	$ 785,197	$ 1,628,477	$ 1,513,654

Accounts receivable, unbilled_3

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) - Schedule of Accounts Receivables and Unbilled Revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Contract Assets [Abstract]
Billed services (accounts receivable)	$ 1,604,945	$ 1,821,855
Allowance for credit losses	(35,303)	(31,533)
Accounts receivable (net)	1,569,642	1,790,322
Unbilled services (unbilled revenue)	1,230,948	951,936
Accounts receivable and unbilled revenue, net	$ 2,800,590	$ 2,742,258

Accounts receivable, unbilled_4

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) - Schedule of Unbilled Services and Unearned Revenue or Payments on Account (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Unbilled services (unbilled revenue)	$ 1,230,948	$ 951,936
Change in unbilled services (unbilled revenue)	$ 279,012
Percentage change in unbilled services (unbilled revenue)	29.30%
Unearned revenue (payments on account)	$ (1,602,526)	(1,654,507)
Change in unearned revenue (payments on account)	$ 51,981
Percentage change in unearned revenue (payments on account)	(3.10%)
Net balance	$ (371,578)	$ (702,571)
Change in net balance	$ 330,993
Percentage change in net balance	(47.10%)

Accounts receivable, unbilled_5

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Increase in unbilled services (unbilled revenue)	$ 279,012
Decrease in unearned revenue (payments on account)	(51,981)
Decrease in net balance	330,993
Revenue, remaining performance obligation	$ 15,800,000	$ 13,900,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation percentage		51%
Revenue, remaining performance obligation, expected timing of satisfaction, period		12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation percentage	49%
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months

Goodwill - Schedule of Goodwill

Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Opening balance	$ 9,022,075	$ 8,971,670
Current period acquisition	2,732	36,750
Foreign exchange movement	(8,258)	13,655
Closing balance	$ 9,016,549	$ 9,022,075

Goodwill - Narrative (Details)

Goodwill - Narrative (Details) - USD ($) $ in Thousands		6 Months Ended			12 Months Ended
	Jan. 09, 2024	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase of subsidiary undertakings (net of cash acquired)			$ 7,831	$ 5,100
Goodwill		$ 9,016,549	9,016,549		$ 9,022,075	$ 8,971,670
Amortization of intangible assets			233,000		459,900
Goodwill, impairment loss			0		$ 0
HumanFirst Inc
Acquired Finite-Lived Intangible Assets [Line Items]
Business combination, consideration transferred	$ 13,300
Payments to acquire businesses, net of cash acquired	7,800
Purchase of subsidiary undertakings (net of cash acquired)	11,800
Cash acquired from acquisition	4,000
Deferred consideration		1,500	$ 1,500
Goodwill	2,700
Intangible assets acquired	$ 9,900
Finite-lived intangible asset, useful life	5 years
Amortization of intangible assets		$ 1,000

Intangible assets - Schedule of

Intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Cost
Total cost	$ 5,155,958	$ 5,147,971
Accumulated amortization	(1,523,604)	(1,292,106)
Net book value	3,632,354	3,855,865
Customer relationships
Cost
Total cost	4,089,261	4,090,393
Order backlog
Cost
Total cost	540,795	541,302
Trade names & brands
Cost
Total cost	204,621	204,653
Patient database
Cost
Total cost	170,348	170,366
Technology assets
Cost
Total cost	$ 150,933	$ 141,257

Intangible assets - Narrative (

Intangible assets - Narrative (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Jan. 09, 2024
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets		$ 233	$ 459.9
HumanFirst Inc
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 1
Intangible assets acquired				$ 9.9

Fair value measurements - Measu

Fair value measurements - Measurement of Fair Value of Major Asset and Liability classed (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Assets:
Available for sale securities (short-term)	$ 0	$ 1,954
Investments in equity - long term	50,220	46,804
Total assets	50,220	48,758
Liabilities:
Total liabilities		2,411
Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments
Liabilities:
Derivative instruments		2,411
Level 1
Assets:
Available for sale securities (short-term)		1,954
Investments in equity - long term	0	0
Total assets	0	1,954
Liabilities:
Total liabilities		0
Level 1 | Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments
Liabilities:
Derivative instruments		0
Level 2
Assets:
Available for sale securities (short-term)		0
Investments in equity - long term	0	0
Total assets	0	0
Liabilities:
Total liabilities		2,411
Level 2 | Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments
Liabilities:
Derivative instruments	0	2,411
Level 3
Assets:
Available for sale securities (short-term)		0
Investments in equity - long term	0	0
Total assets	0	0
Liabilities:
Total liabilities		0
Level 3 | Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments
Liabilities:
Derivative instruments		0
Investments Measured at Net Asset Value
Assets:
Available for sale securities (short-term)		0
Investments in equity - long term	50,220	46,804
Total assets	$ 50,220	46,804
Liabilities:
Total liabilities		0
Investments Measured at Net Asset Value | Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments
Liabilities:
Derivative instruments		$ 0

Fair value measurements - Narra

Fair value measurements - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 50,220	$ 48,758
Long-term debt at fair value	3,469,300	3,793,500
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Level 3 | Fair value, nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	12,648,900	12,878,000
Goodwill at fair value	9,016,500	9,022,100
Net intangible assets at fair value	$ 3,632,400	$ 3,855,900

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 45,789	$ 35,661	$ 45,789	$ 45,390
Severance costs			31,700	34,100
Other restructuring costs			14,100	11,300
Impairment of operating right-of-use assets and related property, plant and equipment			12,559	8,613
Onerous contract provision	1,500		1,500	$ 2,700
Restructuring reserve	26,346		26,346		$ 6,999	$ 6,022
Personnel related liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	21,600		21,600		4,000
Facility liability
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	4,700		4,700		3,000
Restructuring reserve, current	1,200		1,200		1,000
Restructuring reserve, noncurrent	$ 3,500		$ 3,500		$ 2,000

Restructuring - Summary of Rest

Restructuring - Summary of Restructuring Charges (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 45,789	$ 35,661	$ 45,789	$ 45,390

Restructuring - Summary of Deta

Restructuring - Summary of Details of Movement in Restructuring Charges (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Restructuring Reserve [Roll Forward]
Opening provision	$ 6,999	$ 6,022
Charge during the period*	33,230	36,704
Utilization	(13,883)	(35,727)
Closing provision	$ 26,346	$ 6,999

Operating leases - Schedule of

Operating leases - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Operating lease costs	$ 9,287	$ 12,818	$ 22,450	$ 25,689
Income from sub-leases	(301)	(283)	(637)	(561)
Net operating lease costs	$ 8,986	$ 12,535	$ 21,813	$ 25,128

Operating leases - Narrative (D

Operating leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Lessee, Lease, Description [Line Items]
Total lease cost	$ 8,986	$ 12,535	$ 21,813	$ 25,128
Right-of-use assets obtained in exchange for lease obligations	$ 11,000	10,200	$ 46,600	22,500
Weighted average remaining lease term	6 years 10 months 6 days		6 years 10 months 6 days		6 years 8 months 19 days
Weighted average discount rate	3.71%		3.71%		3.29%
Operating lease liabilities, current	$ 36,300		$ 36,300		$ 36,400
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities		Other Liabilities		Other Liabilities
Operating lease liabilities, non-current	$ 145,464		$ 145,464		$ 126,321
Selling, general and administration costs
Lessee, Lease, Description [Line Items]
Total lease cost	8,000	9,300	18,000	19,300
Direct costs
Lessee, Lease, Description [Line Items]
Total lease cost	$ 1,000	$ 3,200	$ 3,800	$ 5,800

Operating leases - Schedule o_2

Operating leases - Schedule of Operating Lease Maturity (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Leases [Abstract]
Year 1	$ 42,160
Year 2	38,053
Year 3	32,707
Year 4	25,968
Year 5	18,176
Thereafter	46,671
Total future minimum lease payments	203,735
Lease imputed interest	(21,976)
Total	$ 181,759

Bank credit lines, loan facil_3

Bank credit lines, loan facilities and notes - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	May 08, 2024	Dec. 31, 2023	Jul. 01, 2021
Debt Instrument [Line Items]
Total debt	$ 3,461,331		$ 3,806,213
Less current portion of debt	(29,762)		(110,150)
Total long-term debt	3,431,569		3,696,063
Less debt issuance costs and debt discount	(23,412)		(30,624)
Total long-term debt, net	$ 3,408,157		$ 3,665,439
Senior Secured Term Loan | Senior Secured Term Loan
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)	7.335%		7.86%	1%
Total debt	$ 961,331		$ 3,251,213
Senior Secured Notes | Senior Secured Notes (the "2026 Notes")
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)	2.875%		2.875%	2.875%
Total debt	$ 500,000		$ 500,000
Senior Secured Notes | Senior Secured Notes (the "2027 Notes")*
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)	5.809%	5.809%
Total debt	$ 750,000		$ 0
Senior Secured Notes | Senior Secured Notes (the "2029 Notes")*
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)	5.849%	5.849%
Total debt	$ 750,000		$ 0
Senior Secured Notes | Senior Secured Notes (the "2034 Notes")*
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)	6%	6%
Total debt	$ 500,000		$ 0
Senior Secured Revolving Loan | Senior Secured Revolving Loan
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)	0%		6.72%
Senior Secured Revolving Loan | Senior Secured Revolving Loan | Senior Secured Revolving Loan
Debt Instrument [Line Items]
Total debt	$ 0		$ 55,000

Bank credit lines, loan facil_4

Bank credit lines, loan facilities and notes - Schedule of Contractual Maturities of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
2024 (remaining)	$ 14,881
2025	29,762
2026	529,762
2027	779,762
2028 and thereafter	2,107,164
Total debt	$ 3,461,331	$ 3,806,213

Bank credit lines, loan facil_5

Bank credit lines, loan facilities and notes - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended						6 Months Ended		12 Months Ended
	May 08, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	May 02, 2023	Jul. 01, 2021
Debt Instrument [Line Items]
Drawdown of credit lines and loan facilities								$ 2,192,480	$ 230,000
Repayments of senior debt								248,000
Line of credit facility, remaining borrowing capacity		$ 0		$ 55,000				0		$ 55,000
Long-term debt at fair value		$ 3,469,300		$ 3,793,500				$ 3,469,300		$ 3,793,500
Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 2,000,000
Debt discount paid	6,800
Senior Secured Term Loan | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0.50%
Senior Secured Term Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								2%
Senior Secured Term Loan | Senior Secured Term Loan
Debt Instrument [Line Items]
Debt instrument, principal amount												$ 5,515,000
Debt instrument, interest rate (in percent)		7.335%		7.86%				7.335%		7.86%		1%
Accelerated charge on repayments		$ 14,900				$ 1,200		$ 14,900	$ 1,200
Senior Secured Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable rate component two | Standard & Poor's, BB Rating
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								1.45%
Senior Secured Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable rate component two | Standard & Poor's, BB+ Rating
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								1.10%
Senior Secured Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable rate component two | Standard & Poor's, BBB- Rating
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0.85%
Senior Secured Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable rate component two | Standard & Poor's, BBB Rating
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0.65%
Senior Secured Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable rate component two | Standard & Poor's, BBB+ Rating
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0.50%
Senior Secured Revolving Loan | Base rate | Variable rate component one
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0.10%
Senior Secured Revolving Loan | Base rate | Maximum | Variable rate component one
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0.45%
Senior Secured Revolving Loan | Base rate | Minimum | Variable rate component one
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)								0%
Senior Secured Revolving Loan | Senior Secured Revolving Loan
Debt Instrument [Line Items]
Debt instrument, interest rate (in percent)		0%		6.72%				0%		6.72%
Senior Secured Revolving Loan | Senior Secured Revolving Loan | Senior Secured Revolving Loan
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity											$ 500,000	$ 300,000
Drawdown of credit lines and loan facilities		$ 143,000	$ 50,000	$ 65,000	$ 75,000	$ 50,000	$ 180,000	$ 193,000		$ 370,000
Senior Secured Notes (the "2026 Notes") | Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, principal amount												$ 500,000
Debt instrument, interest rate (in percent)		2.875%		2.875%				2.875%		2.875%		2.875%
Senior Secured Notes (the "2027 Notes")* | Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 750,000
Debt instrument, interest rate (in percent)	5.809%	5.809%						5.809%
Debt instrument, discount rate on underwriting (in percent)	0.00250
Senior Secured Notes (the "2029 Notes")* | Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 750,000
Debt instrument, interest rate (in percent)	5.849%	5.849%						5.849%
Debt instrument, discount rate on underwriting (in percent)	0.00350
Senior Secured Notes (the "2034 Notes")* | Senior Secured Notes
Debt Instrument [Line Items]
Debt instrument, principal amount	$ 500,000
Debt instrument, interest rate (in percent)	6%	6%						6%
Debt discount paid	$ 500
Debt instrument, discount rate on underwriting (in percent)	0.00450
Debt instrument, redemption price, percentage of principal amount redeemed	99.896%

Bank credit lines, loan facil_6

Bank credit lines, loan facilities and notes - Schedule of Principal Payments on Debt Instruments (Details) - Senior Secured Term Loan - Senior Secured Term Loan - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Debt Instrument [Line Items]
Periodic principal payment	$ 2,014,882	$ 275,000	$ 250,000	$ 300,000	$ 150,000	$ 250,000
Annual principal payment	$ 2,289,882		$ 950,000

Bank credit lines, loan facil_7

Bank credit lines, loan facilities and notes - Schedule of Movement on Debt Instrument (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Debt Instrument [Line Items]
Drawdown of credit lines and loan facilities							$ 2,192,480	$ 230,000
Repayment							2,537,882	580,000
Senior Secured Revolving Loan | Senior Secured Revolving Loan | Senior Secured Revolving Loan
Debt Instrument [Line Items]
Drawdown of credit lines and loan facilities	$ 143,000	$ 50,000	$ 65,000	$ 75,000	$ 50,000	$ 180,000	193,000		$ 370,000
Repayment	193,000	55,000	85,000	50,000	80,000	100,000	248,000		315,000
Total long-term debt, net	$ 0	$ 50,000	$ 55,000	$ 75,000	$ 50,000	$ 80,000	$ 0	$ 50,000	$ 55,000

Derivatives - Narrative (Detail

Derivatives - Narrative (Details) $ in Thousands	3 Months Ended						6 Months Ended
	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Nov. 29, 2022 USD ($) instrument
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Percentage of debt hedged by fixed interest rate	72%		13%				72%
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]			Other liabilities
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]			Non-current other liabilities
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax	$ (4,100)				$ 14,000		$ 5,000	$ 10,100
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	(12,800)				1,400		$ (13,500)	$ 3,600
Senior Secured Term Loan | Senior Secured Term Loan
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Periodic principal payment	$ 2,014,882	$ 275,000	$ 250,000	$ 300,000	$ 150,000	$ 250,000
Interest Rate Caps | Total derivatives designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of interest rate derivatives held | instrument									2
Derivative, notional amount									$ 2,101,000
Derivative, fixed interest rate									0.42%
Derivative, variable interest rate, reference rate in excess of									4.75%
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount									$ 1,101,000
Derivative, fixed interest rate									3.40%
Total derivatives designated as hedging instruments | Total derivatives designated as hedging instruments | Level 2
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative liability, current			1,900
Derivative liability, noncurrent			$ 500

Derivatives - Effect of Derivat

Derivatives - Effect of Derivative Financial Instruments on Statement of Financial Position (Details) - Total derivatives designated as hedging instruments - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Interest Rate Caps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Asset	$ 0	$ 0
Liability	0	1,871
Notional	0	1,600,606
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Asset	0	0
Liability	0	540
Notional	0	1,100,606
Total derivatives designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Liability		2,411
Notional	0	2,701,212
Total derivatives designated as hedging instruments | Level 2
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Asset	0	0
Liability	$ 0	$ 2,411

Income taxes - Schedule of Comp

Income taxes - Schedule of Components of Tax (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Tax expense	$ 23,344	$ 9,629	$ 51,668	$ 23,902

Income taxes - Narrative (Detai

Income taxes - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefit	$ 196.1	$ 187.1
Items generating unrecognized tax benefits	162.4	160
Interest and related penalties	$ 33.7	$ 27.1

Net income per ordinary share -

Net income per ordinary share - Schedule of Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Weighted average number of ordinary shares outstanding for basic net income per ordinary share (in shares)	82,738,765	81,999,746	82,658,984	81,892,662
Effect of dilutive share options and other awards outstanding under share based compensation programs (in shares)	622,076	628,187	601,160	724,729
Weighted average number of ordinary shares outstanding for diluted net income per ordinary share (in shares)	83,360,841	82,627,933	83,260,144	82,617,391

Net income per ordinary share_2

Net income per ordinary share - Schedule of Reconciliation of Net Income Attributable to the Group (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net income per Ordinary Share:
Basic (in USD per share)	$ 1.78	$ 1.41	$ 4.04	$ 2.84
Diluted (in USD per share)	$ 1.76	$ 1.40	$ 4.02	$ 2.81

Share-based awards - Summary of

Share-based awards - Summary of Stock Option Activity (Details) - Employee Stock Option			6 Months Ended
	Jun. 30, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Jun. 30, 2024 $ / shares shares
Options Outstanding Number of Shares
Outstanding at beginning of period (in shares) | shares			902,806
Granted (in shares) | shares			68,380
Exercised (in shares) | shares			(201,654)
Outstanding at end of period (in shares) | shares	769,532	902,806	769,532
Exercisable at end of period (in shares) | shares	535,883		535,883
Weighted Average Exercise Price
Outstanding at beginning of period (in USD per share) | $ / shares			$ 142.96
Granted (in USD per share) | $ / shares			325.51
Exercised (in USD per share) | $ / shares			107.30
Outstanding at end of period (in USD per share) | $ / shares	$ 168.52	$ 142.96	168.52
Exercisable at end of period (in USD per share) | $ / shares	$ 134.89		$ 134.89
Weighted Average Remaining Contractual Life
Weighted average contractual term of options outstanding	4 years 6 months 18 days	4 years 5 months 1 day
Weighted average contractual term of options exercisable	3 years 9 months 21 days

Share-based awards - Narrative

Share-based awards - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended	12 Months Ended	62 Months Ended
	Jun. 30, 2024	May 11, 2015	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2024	May 16, 2019
Employee Stock Option
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Number of shares exercisable (in shares)	535,883		535,883		535,883
Weighted average contractual term of options exercisable	3 years 9 months 21 days
Weighted average exercise price of options exercisble (USD per share)	$ 134.89		$ 134.89		$ 134.89
Restricted stock units 2013
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Additional ordinary shares which have been reserved for issuance (in shares)		2,500,000
Ordinary shares which have been reserved for issuance (in shares)		4,100,000
Consultants Restricted Stock Units 2019
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Ordinary shares which have been reserved for issuance (in shares)						250,000
Consultants Restricted Stock Units 2019 | Non-executive directors
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Shares vesting period					12 months
Performance Share Unit (PSUs)
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Fair value of stock units vested			$ 1.8	$ 7.5
Restricted Stock Units (RSUs)
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Fair value of stock units vested			$ 24.3	$ 28.3
PSUs based on service and EPS targets | Maximum
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Stock units to be granted (in shares)	85,659		85,659		85,659

Share-based awards - Schedule o

Share-based awards - Schedule of Weighted Average Fair Values and Assumptions Used (Details) - Employee Stock Option - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 115.76	$ 85.12
Assumptions:
Expected volatility	36%	33%
Dividend yield	0%	0%
Risk-free interest rate	4.20%	4.18%
Expected life	4 years 3 months 18 days	5 years

Share-based awards - Summary _2

Share-based awards - Summary of RSU and PSU Activity (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Performance Share Unit (PSUs)
Outstanding Number of Shares
Outstanding at beginning of period (in shares) | shares	105,256
Granted (in shares) | shares	48,626
Shares vested (in shares) | shares	(9,975)
Forfeited (in shares) | shares	(72,764)
Outstanding at end of period (in shares) | shares	71,143
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in USD per share) | $ / shares	$ 226.29
Granted (in USD per share) | $ / shares	325.51
Shares vested (in USD per share) | $ / shares	177.38
Forfeited (in USD per share) | $ / shares	252.86
Outstanding at end of period (in USD per share) | $ / shares	$ 273.79
Restricted Stock Units (RSUs)
Outstanding Number of Shares
Outstanding at beginning of period (in shares) | shares	621,011
Granted (in shares) | shares	237,539
Shares vested (in shares) | shares	(109,885)
Forfeited (in shares) | shares	(39,114)
Outstanding at end of period (in shares) | shares	709,551
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in USD per share) | $ / shares	$ 218.27
Granted (in USD per share) | $ / shares	318.49
Shares vested (in USD per share) | $ / shares	220.87
Forfeited (in USD per share) | $ / shares	221.86
Outstanding at end of period (in USD per share) | $ / shares	$ 251.22

Share-based awards - Schedule_2

Share-based awards - Schedule of Non-Cash Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 14,964	$ 16,598	$ 28,145	$ 31,357
Direct costs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	7,299	6,420	14,020	12,088
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 7,665	$ 10,178	$ 14,125	$ 19,269

Share capital (Details)

Share capital (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Feb. 20, 2024
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount		$ 500
Buyback Program | Maximum
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, authorized percentage	10%

Business Segment and Geograph_3

Business Segment and Geographical Information - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	1

Business Segment and Geograph_4

Business Segment and Geographical Information - Schedule of Distribution of Revenue by Geographical Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Revenue	$ 2,120,159	$ 2,020,251	$ 4,210,545	$ 3,998,829
Ireland
Segment Reporting Information [Line Items]
Revenue	702,858	593,407	1,355,543	1,105,241
Rest of Europe
Segment Reporting Information [Line Items]
Revenue	384,214	373,810	774,429	788,033
U.S.
Segment Reporting Information [Line Items]
Revenue	792,370	848,019	1,601,855	1,692,423
Rest of World
Segment Reporting Information [Line Items]
Revenue	$ 240,717	$ 205,015	$ 478,718	$ 413,132

Business Segment and Geograph_5

Business Segment and Geographical Information - Schedule of Distribution of Income from Operations by Geographical Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
Income from operations	$ 229,857	$ 209,484	$ 515,354	$ 426,273
Ireland
Segment Reporting Information [Line Items]
Income from operations	108,381	125,896	245,111	177,223
Rest of Europe
Segment Reporting Information [Line Items]
Income from operations	39,629	22,489	93,140	82,255
U.S.
Segment Reporting Information [Line Items]
Income from operations	62,656	55,744	139,555	143,833
Rest of World
Segment Reporting Information [Line Items]
Income from operations	$ 19,191	$ 5,355	$ 37,548	$ 22,962

Business Segment and Geograph_6

Business Segment and Geographical Information - Schedule of Distribution of Depreciation and Amortization by Geographical Area (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Long-lived assets	$ 503,626	$ 501,517
Ireland
Segment Reporting Information [Line Items]
Long-lived assets	206,141	199,051
Rest of Europe
Segment Reporting Information [Line Items]
Long-lived assets	90,097	94,046
U.S.
Segment Reporting Information [Line Items]
Long-lived assets	152,706	159,245
Rest of World
Segment Reporting Information [Line Items]
Long-lived assets	$ 54,682	$ 49,175